Chong Kun Dang (185750) Stock Price, Fundamentals & Analysis

What 185750 does

Chong Kun Dang (185750) is a stock listed on the Korea Exchange in the Healthcare sector, specifically within the Drug Manufacturers – Specialty & Generic industry. The company manufactures, markets, and sells prescription drugs for conditions such as hypertension, high cholesterol, and diabetes, along with immunosuppressants, over-the-counter medicines, and consumer health products like insecticides and hair dye. Founded in 1941 and headquartered in Seoul, South Korea, Chong Kun Dang employs 2,170 people. Within the Korean market, it operates alongside peers such as SK Biopharm (326030), Daewoong Pharmaceutical (069620), and Hanall Biopharma (009420).

Key numbers explained

• The current price is 64,900 KRW, reflecting a +0.46% move today.
• The marketCap of 855.13B KRW represents the total market value of all outstanding shares.
• The forward P/E ratio of 11.9 divides the current price by expected future earnings, offering a sense of how the market values the company’s growth prospects relative to its peers.
• The dividend yield of 0.77% shows the annual dividend as a percentage of the current share price, indicating the cash return to shareholders.
• The exDividendDate of 29 dec. 2025 is the date by which an investor must own the stock to be eligible for the upcoming dividend payment.
• A beta of 0.25 suggests the stock’s price tends to move less than the overall market, often interpreted as lower volatility.
• The 52-week range of 63,000 – 98,100 shows the lowest and highest traded prices over the past year, with the current price near the lower end of that span.
• The debt-to-equity ratio of 43 compares total debt to shareholders’ equity, helping assess the company’s financial leverage.

What to watch

Investors tracking Chong Kun Dang may monitor its revenue growth, which has been 10% year over year on trailing 12-month revenue of 1,78T KRW. Profitability metrics such as the 4.5% profitMargin and 3.9% operatingMargin provide insight into how efficiently the company converts sales into earnings. The 8.2% returnOnEquity measures how effectively the company uses shareholder capital to generate profit. As a Healthcare stock, Chong Kun Dang can be influenced by regulatory changes, drug approval cycles, and competitive dynamics within the Korean pharmaceutical landscape, where peers like Hanmi Pharm (128940) and Samsung Epis (0126Z0) also operate.